Today’s most popular dermal fillers include Restylane, Juvederm and Botox, and hyaluronic acid fillers ar frequently used to correct wrinkles and fine lines, reshape and contour the face, and to create a more youthful appearance. Researchers are now reviewing an innovative dermal filler called ATX-104.
Unlike regular injectables that are simply injected into the skin to produce immediate results, the ATX-104 works only after it comes into contact with an external light source. After it is injected, the filler is shaped and polymerized transdermally with the help of external light.
The ATX-104 filler is based on KYTHERA’s proprietary photochemistry platform and has been developed at Johns Hopkins University. Scientists are studying the effects of the light reaction, and working on ways to optimize the filler so that it can create dramatic results and be used to reshape the face.
Different types of injectable fillers can produce different results based on the strength of the filler, and the person’s existing skin conditions. Hyaluronic acid fillers such as Juvederm and Restylane are commonly used to reshape the face, fill out wrinkles and lines around the mouth and nose, and to correct sagging skin. Botox is most commonly used to correct deep wrinkles on the forehead, but also has other uses including treating headaches and migraines, or stopping sweating.
So far, the ATX-104 system has been able to produce better results than many of the fillers that are readily available. It is still undergoing testing, and Kythera Biopharmaceuticals has announced that the first in-human trial of the light-activated filler was successful.
Kythera Biopharmaceuticals is a biotechnology company based out of California, and was started by former employees of Amgen. It has about $40 million in funding, and is working on the ATX-104 system, along with three other products designed specifically for the aesthetic market.